AbbVie (ABBV) Sues CMS Over Proposed Botox Price Controls

AbbVie (ABBV) filed a lawsuit on February 11, 2026, against the Centers for Medicare & Medicaid Services (CMS), challenging proposed price controls on its blockbuster drug Botox. The agency had notified providers it would implement a 25% price ceiling on the injectable treatment, effective January 1, 2026. AbbVie argues the controls would reduce access and harm revenue, potentially affecting its financial performance and stock price. The company seeks an injunction to block the implementation pending litigation.